Two immune check point inhibitors targeting PD-1 have been recently approved by the FDA for HNSCC patients, albeit the rate of response is approximately 20%, lower than that of other malignancies, such as melanoma [6–14]. Here, PDCD1 is linked to head and neck squamous cell carcinoma.